Viewing data from:

DEPODUR

NDA

MORPHINE SULFATE | N021671 | PACIRA PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain3 active DMFs5 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

SPECGX LLCMORPHINE SULFATE

DMF 58571985

NORAMCO LLCMORPHINE SULFATE

DMF 69671987

VERANOVA LPMORPHINE SULFATE USP

DMF 215882008

PENICK CORPInactiveMORPHINE SULFATE

DMF 66801986

MACFARLAN SMITH LTDInactiveMORPHINE SULFATE

DMF 83281989

MALLINCKRODT INCInactiveMORPHINE SULFATE INJECTION USP

DMF 115291995

ELAN PHARMA LTDInactiveMORPHINE SULFATE

DMF 128081997

SIEGFRIED USA LLCInactiveMORPHINE SULFATE USP

DMF 196932006

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

7 letters from Drugs@FDA

Date	Submission	Document
Nov 10, 2009	SUPPL -20	View Letter (PDF)
Jan 9, 2008	SUPPL -19	View Letter (PDF)
Feb 23, 2007	SUPPL -15	View Letter (PDF)
Jan 25, 2007	SUPPL -14	View Letter (PDF)
May 25, 2006	SUPPL -4	View Letter (PDF)
Aug 12, 2004	SUPPL -2	View Letter (PDF)
May 26, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — 10MG/ML (10MG/ML)

0 patents0 exclusivities▴

INJECTABLE, LIPOSOMAL;EPIDURAL | Approved: May 18, 2004

No patent or exclusivity listings for this strength.

#002 — 15MG/1.5ML (10MG/ML)

0 patents0 exclusivities▾

INJECTABLE, LIPOSOMAL;EPIDURAL | Approved: May 18, 2004

#003 — 20MG/2ML (10MG/ML)

0 patents0 exclusivities▾

INJECTABLE, LIPOSOMAL;EPIDURAL | Approved: May 18, 2004